Advanced in Excessive Daytime Sleepiness

Dr. Andrew O. Schreiber

Neurosurgery | Neurology
Regents Of The University Of California
100 Ucla Medical Plz, Suite 460, 
Los Angeles, CA 
46 Years of Experience
Advanced in Excessive Daytime Sleepiness
Regents Of The University Of California
100 Ucla Medical Plz, Suite 460, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Schreiber is a Neurosurgery specialist and a Neurologist in Los Angeles, California. Dr. Schreiber has been practicing medicine for over 46 years and is rated as an Advanced provider by MediFind in the treatment of Excessive Daytime Sleepiness. His top areas of expertise are Narcolepsy, Excessive Daytime Sleepiness, Spinal Stenosis, and Obstructive Sleep Apnea.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 4 clinical trials in the study of Excessive Daytime Sleepiness.

Graduate Year
1979
Specialties
Neurosurgery
Neurology
Licenses
Neurological Surgery in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

REGENTS OF THE UNIVERSITY OF CALIFORNIA
100 Ucla Medical Plz, Suite 460, Los Angeles, CA 90024
Other Locations
1535 E 17th St, Suite 101, Santa Ana, CA 92705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: AD109, AD504, Atomoxetine Hydrochloride
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Distinguished in Excessive Daytime Sleepiness
Dr. Alon Y. Avidan
Neurology | Sleep Medicine
Distinguished in Excessive Daytime Sleepiness
Dr. Alon Y. Avidan
Neurology | Sleep Medicine

The Regents Of The University Of California

10833 Le Conte Ave, 
Los Angeles, CA 
 (0.1 miles away)
310-825-0650
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alon Avidan is a Neurologist and a Sleep Medicine provider in Los Angeles, California. Dr. Avidan is rated as a Distinguished provider by MediFind in the treatment of Excessive Daytime Sleepiness. His top areas of expertise are Drowsiness, Obstructive Sleep Apnea, REM Behavior Disorder, and Restless Legs Syndrome.

Advanced in Excessive Daytime Sleepiness
Dr. Errajith Desilva
Neurology | Sleep Medicine
Advanced in Excessive Daytime Sleepiness
Dr. Errajith Desilva
Neurology | Sleep Medicine
101 East Valencia Mesa Drive, Suite 7B, 
Fullerton, CA 
 (32.0 miles away)
714-446-7240
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Errajith Desilva is a Neurologist and a Sleep Medicine provider in Fullerton, California. Dr. Desilva is rated as an Advanced provider by MediFind in the treatment of Excessive Daytime Sleepiness. His top areas of expertise are Obstructive Sleep Apnea, Insomnia, Drowsiness, Gastrostomy, and Endoscopy. Dr. Desilva is currently accepting new patients.

Advanced in Excessive Daytime Sleepiness
Dr. Arun Ramachandran
Sleep Medicine | Neurology
Advanced in Excessive Daytime Sleepiness
Dr. Arun Ramachandran
Sleep Medicine | Neurology

Cedars-Sinai Medical Care Foundation

8635 W 3rd St, Suite 465w, 
Los Angeles, CA 
 (3.7 miles away)
310-423-0674
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Ramachandran is a Sleep Medicine specialist and a Neurologist in Los Angeles, California. Dr. Ramachandran is rated as an Advanced provider by MediFind in the treatment of Excessive Daytime Sleepiness. His top areas of expertise are Obstructive Sleep Apnea, Drowsiness, Excessive Daytime Sleepiness, and Narcolepsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schreiber's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile